[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518522":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":26,"locations":36,"responsibleParty":67,"collaborators":10,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":10,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":10,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Tianjin Medical University Second Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Oncolytic adenovirus(H101) combined with PD-1 inhibitors",null,"This study observed 2-4 treatment cycles. For the convenience of statistics, this project stipulated that the first combined medication (v1) after the patient was enrolled in this study was administered with oncolytic virus (recombinant human adenovirus type 5) by intratumoral injection or intrapleural injection on the 1-3 days. On the 4th or 5th day, PD-1 injection was administered once per cycle. The completion of two visits in this study is considered a completed case, and subsequent treatment is determined jointly by the researcher and the subject.",[13,14],"Drug: Oncolytic Adenovirus H101","Drug: Programmed death receptor-1 inhibitor",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Oncolytic Adenovirus H101","The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles",[9],[22],"Recombinant Human Type-5 Adenovirus",{"type":17,"name":24,"description":19,"armGroupLabels":25,"otherNames":10},"Programmed death receptor-1 inhibitor",[9],[27,32],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Haitao Wang, Ph.D","CONTACT","+86-022-88326385","peterrock2000@126.com",{"name":33,"role":29,"phone":34,"phoneExt":10,"email":35},"Jinhuan Wang, Ph.D","+86-022-88326610","wjhhappy2008@163.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":10,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Tianjin Medical Unversity Second Hospital","RECRUITING","Tianjin","Tianjin Municipality","China","CN",{"type":45,"coordinates":46},"Point",[47,48],117.17667,39.14222,{"lat":48,"lon":47},[51,52,55,58,61,63,65],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":53,"role":29,"phone":34,"phoneExt":10,"email":54},"Lili Wang, MM","wangliliaigang@163.com",{"name":56,"role":57,"phone":10,"phoneExt":10,"email":10},"Haitao Wang","PRINCIPAL_INVESTIGATOR",{"name":59,"role":60,"phone":10,"phoneExt":10,"email":10},"Lili Wang","SUB_INVESTIGATOR",{"name":62,"role":60,"phone":10,"phoneExt":10,"email":10},"Jinhuan Wang",{"name":64,"role":60,"phone":10,"phoneExt":10,"email":10},"Dingkun Hou",{"name":66,"role":60,"phone":10,"phoneExt":10,"email":10},"Lei Wang",{"type":68,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100518522","oncolytic-adenovirush101-combined-with-pd-1-inhibitors-in-patients-with-advanced-malignant-pleural-mesothelioma-100518522",false,"NCT06031636","Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma","Observation of the Efficacy and Safety of Oncolytic Adenovirus Injection Combined With Programmed Death Receptor Inhibitors in Treatment of Advanced Malignant Pleural Mesothelioma : a Single Center, Prospective, Case Registration Study","Inclusion Criteria:\n\n1. Age 18-75 years old (including boundary values), regardless of gender.\n2. Confirmed as late stage MPM patients who have failed immunotherapy.\n3. The patient or their legal representative can understand and sign the informed consent form.\n4. At least one lesion that can safely undergo intratumoral injection or intrapleural injection of oncolytic adenovirus as the target lesion, with a diameter of spiral CT ≥ 1cm or ordinary CT ≥ 2cm, and can be measured through imaging methods.\n5. ECOG score 0-2.\n\nExclusion Criteria:\n\n1. Physicians participating in the study believe that patients may not be able to provide continuous follow-up information.\n2. Any uncontrollable clinical problems (such as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases).\n3. Contraindications to relevant drugs (such as oncolytic adenoviruses, PD-1 inhibitors, etc.)","ALL","18 Years","75 Years",{"count":80,"type":81},15,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors.",[85],"Malignant Pleural Mesothelioma, Advanced",[85,87,88],"Oncolytic Adenovirus","Programmed Death Receptor","2023-09-02",{"date":91,"type":92},"2023-09-11","ACTUAL",{"date":94,"type":92},"2023-07-20",{"date":96,"type":81},"2026-07-31",{"name":5,"class":6},1]